First lab-developed test specifically designed to detect Monkeypox virus DNA to receive emergency use authorization during the monkeypox public health emergency
As the first laboratory to validate Ki-67 IHC MIB-1 pharmDx Quest plans to make testing available nationally by the end of October 2021
Multi-regional strategic initiatives agreement designed to improve efficiency in care delivery, reduce cost, and enhance experience for health care consumers and providers
Company also receives new FDA emergency use authorizations for use of self-collection molecular diagnostic kit on the Hologic and Roche platforms
Gold Standard accreditation signifies commitment to reducing employee cancer risk
Company to make the device available through broad range of healthcare, state, employer and consumer-initiated channels
COVID-19 molecular diagnostic and serology antibody testing at core of new suite of services
Acquisition adds platform in gene variant interpretation based on next generation sequencing
The GDN brings together leading diagnostics services providers to share expertise and drive worldwide diagnostics innovation
eCCF dramatically improves efficiency and time savings in workplace drug testing
Largest percentage of children with very high blood lead levels concentrated in six regions, including in New York, Pennsylvania and Ohio
34-gene panel for assessing risk of 15 inherited cancers among new Quest Vantage™ test services to be highlighted during the 2016 ASCO Annual Meeting
First test from a commercial lab to receive emergency use authorization for testing patients in the United States, including Puerto Rico, for Zika infection
Integrated with nearly 600 EHR platforms to align clinical management with quality, utilization and financial performance goals
Third offering in Quest's precision medicine menu for oncology immunotherapies
KEYTRUDA is Merck's anti-PD-1 therapy for metastatic non-small cell lung cancer whose tumors express PD-L1 with disease progression on or after platinum-containing chemotherapy
System from Quest Diagnostics' products business is first FDA-cleared Herpes Simplex Virus 1 and 2 test that uses genital swab or cerebrospinal fluid (CSF) specimen collection
New prenatal screening service provides actionable information for women with high-risk pregnancies
